Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty

Am J Ophthalmol. 2007 Aug;144(2):318-9. doi: 10.1016/j.ajo.2007.03.028.

Abstract

Purpose: To assess the impact of duration of topical steroid treatment on the incidence of endothelial graft rejection after normal-risk penetrating keratoplasty (PK).

Design: Prospective, institutional, longitudinal, randomized interventional trial including 406 eyes (age 52 +/- 19 years; follow-up 42 +/- 18 months).

Methods: Postoperative treatment started with prednisolone acetate 1% eye drops five times daily and was tapered over the first six months. Patients were then randomized into either short-term (stop topical steroid treatment) or long-term treatment (continue steroids once daily for 12 months).

Results: During follow-up, 29 eyes (7.1%) developed an episode of endothelial graft rejection. Graft rejections were significantly more common in the short-term (19 of 202; 9.1%) compared with the long-term treatment group (10 of 204: 4.9%; P = .001).

Conclusions: Long-term, low-dose topical steroid treatment protects against immunologic graft rejections.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage*
  • Corneal Diseases / surgery*
  • Endothelium, Corneal / pathology
  • Female
  • Follow-Up Studies
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects*
  • Humans
  • Keratoplasty, Penetrating*
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Prednisolone / administration & dosage
  • Prednisolone / analogs & derivatives*
  • Prodrugs
  • Prospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Ophthalmic Solutions
  • Prodrugs
  • prednisolone acetate
  • Prednisolone